Psychedelic clinical trial hubs
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap.
These pages group registered studies by the substance they name, by registry status and by phase. Each page shows counts and links to the registry record for every study it lists. Registered studies are listings, not findings.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
By substance
- Psilocybin: 308 studies
- MDMA: 109 studies
- LSD: 49 studies
- DMT: 37 studies
- 5-MeO-DMT: 17 studies
- Ayahuasca: 9 studies
- Ketamine: 458 studies
- Ibogaine: 9 studies
By registry status
- Recruiting: 213 studies
- Not yet recruiting: 65 studies
- Active, not recruiting: 60 studies
- Enrolling by invitation: 12 studies
- Completed: 400 studies
- Terminated: 52 studies
- Suspended: 6 studies
- Withdrawn: 47 studies
By phase
- Early Phase 1: 64 studies
- Phase 1: 254 studies
- Phase 2: 323 studies
- Phase 3: 72 studies
- Phase 4: 65 studies
- Phase not applicable: 97 studies
The interactive map shows where studies take place, and the Learn page explains the background.